Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
The Oncologist · 17.03.2023 · 28 (3) · 258-267
DOI: 10.1093/oncolo/oyac253 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 26.12.2022. Verfasst von Fabrice Barlesi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.
Abstract (Originalsprache)
Background
Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor beta receptor II (a TGF-β “trap”) fused to a human immunoglobulin G1 monoclonal antibody blocking programmed cell death 1 ligand 1 (PD-L1). We report the efficacy and safety in patients with non-small cell lung cancer (NSCLC) that progressed following anti-PD-(L)1 therapy. Materials and Methods In this expansion cohort of NCT02517398—a global, open-label, phase I trial—adults with advanced NSCLC that progressed following chemotherapy and was primary refractory or had acquired resistance to anti-PD-(L)1 treatment received intravenous bintrafusp alfa 1200 mg every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal. The primary endpoint was best overall response (by Response Evaluation Criteria in Solid Tumors version 1.1 adjudicated by independent review committee); secondary endpoints included safety.
Results
Eighty-three eligible patients (62 [74.7%] treated with ≥3 prior therapies) received bintrafusp alfa. Four patients (3 primary refractory, 1 acquired resistant) had confirmed partial responses (objective response rate, 4.8%; 95% CI, 1.3%-11.9%), and 9 had stable disease. Tumor cell PD-L1 expression was not associated with response. Nineteen patients (22.9%) experienced grade ≥3 treatment-related adverse events, most commonly asthenia (3 [3.6%]) and fatigue, eczema, and pruritus (2 each [2.4%]). One patient had grade 4 amylase increased. One patient died during treatment for pneumonia before initiation of bintrafusp alfa.
Conclusion
Although the primary endpoint was not met, bintrafusp alfa showed some clinical activity and a manageable safety profile in patients with heavily pretreated NSCLC, including prior anti-PD-(L)1 therapy. Tumor responses occurred irrespective of whether disease was primary refractory or had acquired resistance to prior anti-PD-(L)1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
- Service d'oncologie médicale CLCC Georges-François Leclerc, Dijon, France.
- Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain.
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Oncology, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Research, Oncology Consultants, Houston, TX, USA.
ORCID-Profile: James L Gulley
Förderung
- Merck
Zitieren
APA
Barlesi, F., Isambert, N., Felip, E., Cho, B. C., Lee, D. H., Peguero, J., Jerusalem, G., Penel, N., Saada-Bouzid, E., Garrido, P., Helwig, C., Locke, G., Ojalvo, L. S., & Gulley, J. L. (2023). Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist, 28(3), 258-267. https://doi.org/10.1093/oncolo/oyac253
Vancouver
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist. 2023;28(3):258-267. doi:10.1093/oncolo/oyac253
BibTeX
@article{Barlesi2023,
author = {Barlesi, Fabrice and Isambert, Nicolas and Felip, Enriqueta and Cho, Byoung Chul and Lee, Dae Ho and Peguero, Julio and Jerusalem, Guy and Penel, Nicolas and Saada-Bouzid, Esma and Garrido, Pilar and Helwig, Christoph and Locke, George and Ojalvo, Laureen S and Gulley, James L},
title = {Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {3},
pages = {258--267},
doi = {10.1093/oncolo/oyac253}
}
EUVIMED